So far, it’s been a tremendous year at Pledge Therapeutics! We have expanded both our US and EU teams in the last 6 months. We're excited to welcome: US team (Canton, MA): Nagraj Mani, Senior Director, Virology Erin Deans, Scientist, Virology Consuelo Beatriz Correa Sierra, Senior Research Associate, Virology Rebecca Lashin (Riding), Senior Scientist, Immuno-Oncology Xue Yao, Scientist, Immuno-Oncology Krishna Kandala, Senior Associate, Business Development, Strategy & Operations Nick Hamilton, Postdoctoral Associate, Computational Chemist EU team (Leuven, BE): Senne Sienaert, Research Associate, Structural Biology As we grow our R&D, Computational Chemistry, and Business Development teams, we've opened some key positions to support our efforts at this exciting time in our growth journey. Please reach out to Maria Martin to inquire about these new positions or to join our talent network for future opportunities! #Biotech, #Startup # #Resarch #nowhiring #joinourteam www.pledge-tx.com
Pledge Therapeutics
Biotechnology Research
Canton, MA 7,104 followers
Harnessing advanced biophysical & structural technologies to design transformative medicines against challenging targets
Über uns
Pledge Therapeutics efforts have given rise to a constellation of exciting discoveries, spanning from early drug hits to preclinical candidates. Our success is based on the rapid translation of clinical and disease insights into target identification and development of novel drug molecules. At the core of our effort is the integration of structural and biophysical knowledge of disease targets to accelerate the pace and success of drug development.
- Website
-
https://pledge-tx.com
External link for Pledge Therapeutics
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 11-50 Mitarbeiter
- Hauptsitz
- Canton, MA
- Typ
- In Privatbesitz
Standorte
-
Primäre
Wegbeschreibung erhalten
Canton, MA 02021, US
-
Wegbeschreibung erhalten
Gaston Geenslaan 1
Leuven , 3001, BE
Employees at Pledge Therapeutics
-
Mark Spyvee
CEO at RexChem Research
-
Maria Martin
People and Operations @Pledge Therapeutics
-
Asanga Bandara
Principal Computational Chemist at Pledge Therapeutics | Developing Physics and ML augmented Drug discovery solutions
-
Stephen Weeks
Director of Structural Biology and Biophysics
Aktualisierungen
-
We are proud to see Louise Sykora graduate magna cum laude from KU Leuven with a Master’s in Biophysics, Biochemistry, and Biotechnology: Congratulations! It's thrilling to see how the passion for science and for pushing the boundaries of discovery are contagious! Keep up the amazing work—you're now officially part of our alumni crew; drop by anytime; always welcome. Congrats again on this fantastic milestone! Pledge Therapeutics #teamwork #STEMGraduation #ProudAlumni
Dear network, I am excited to announce that I graduated magna cum laude with a Master’s degree in Biophysics, Biochemistry, and Biotechnology from KU Leuven. Over the past year, I had the privilege of conducting my master’s thesis under the mentorship of Dr. Stephen Weeks at Pledge Therapeutics. My thesis, titled “Characterization of Human Histone Methyltransferases,” involved nine months of rigorous research, resulting in a score of 80%. This experience not only solidified my passion for biochemistry but also provided me with invaluable hands-on experience in a professional setting. I was involved in developing a new biochemical assay for high-throughput screening and validating small molecule inhibitors, tackling the entire process from cloning and recombinant production to assay design and optimization. My efforts culminated in a successful pilot screen and a well-received thesis presentation. I am profoundly grateful to the team at Pledge Therapeutics and my family for their support and the opportunities provided. I am eager to leverage my skills and passion in the field of biochemistry and biotechnology, contributing to scientific advancements.
-
-
Pledge Therapeutics and our CEO Dr. Ali Munawar are immersed in the Immuno-Oncology Summit Europe 2024 in London. With our groundbreaking advancements in our Immuno-Oncology pipeline, we look forward to lively breakout discussions, networking opportunities, and connecting with global leaders in the Immuno-Oncology space. #ImmunoOncology #IOSummitUK #DrugDiscovery #Biopharma Our Immuno-Oncology programs reside under Conformation-X Therapeutics a company affiliated with Pledge Therapeutics. https://lnkd.in/dgE7-xS
8th Annual Immuno-Oncology Summit Europe | 23-25 April 2024 | London, UK & Online
immuno-oncologyeurope.com
-
We are thrilled to announce that Conformation-X Therapeutics, affiliated with Pledge Therapeutics, has emerged from stealth mode, securing an additional $3.65 million in funding. This brings our total raised to over $13.5 million since inception. The successive rounds of funding are a testament to our investors’ confidence in the innovation and rigor behind our efforts. Read more: https://lnkd.in/erAF-B9c Conformation-X Therapeutics is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery platform.
Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
businesswire.com